Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma programme. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Arcellx Provides First Quarter 2024 Financial Results
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Arcellx to Participate in Two Upcoming Investor Conferences
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.
Arcellx, Kite aim to keep chipping away at Carvykti advantage
REDWOOD CITY, Calif., Dec. 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new clinical data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel). Anito-cel utilizes a novel D-Domain BCMA binder that is compact and stable, which results in a drug product with a high proportion of CAR+ cells and high surface expression, potentially enhancing antigen binding and more efficient Multiple Myeloma cell killing.